Skip to main content
profile image
Selected Works of Carlo B. Bifulco, M.D.
Article
Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.
Journal of Clinical Oncology (2019)
  • Jerome Galon, French Institute of Health and Medical Research
  • Fabienne Hermitte, HalioDx, Marseille, France;
  • Bernhard Mlecnik, French Institute of Health and Medical Research
  • Florence Marliot, French Institute of Health and Medical Research
  • Carlo Bruno Bifulco, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Alessandro Lugli, University of Bern
  • Iris D. Nagtegaal, Department of Pathology, Radboud UMC, Nijmegen, Netherlands;
  • Arndt Hartmann, University of Erlangen-Nuremberg
  • Marc Van Den Eynde, UniversitĂ© catholique de Louvain
  • Michael H. A. Roehrl, Memorial Sloan Kettering Cancer Center
  • Pamela S Ohashi, Princess Margaret Cancer Centre
  • Eva Zavadova, First Faculty of Medicine, Charles University in Prague
  • Toshihiko Torigoe, Sapporo Medical University
  • Prabhudas S. Patel, The Gujarat Cancer and Research Institute, Ahmedabad, India;
  • Yili Wang, Institute of Cancer Research, Xian, China;
  • Yutaka Kawakami, Keio University
  • Francesco Marincola, AbbVie
  • Paolo Antonio Ascierto, National Tumour Institute Fondazione G. Pascale, Naples, Italy;
  • Bernard A. Fox, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Franck Pages, French Institute of Health and Medical Research
Link
Disciplines
Publication Date
January 29, 2019
DOI
10.1200/JCO.2019.37.4_SUPPL.487
Citation Information
Jerome Galon, Fabienne Hermitte, Bernhard Mlecnik, Florence Marliot, et al.. "Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided." Journal of Clinical Oncology Vol. 37 (2019) p. 487 - 487
Available at: http://works.bepress.com/carlo-bifulco/64/